NeoGenomics, Inc. (NASDAQ:NEO) Given Average Rating of “Moderate Buy” by Brokerages

NeoGenomics, Inc. (NASDAQ:NEO) has been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $19.89.

A number of research analysts recently commented on NEO shares. Benchmark reaffirmed a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a research note on Tuesday, September 24th. Stephens reaffirmed an “overweight” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Tuesday, July 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a research note on Wednesday, September 25th.

NeoGenomics Stock Up 1.0 %

NEO stock opened at $14.14 on Tuesday. The company has a market cap of $1.81 billion, a PE ratio of -22.81 and a beta of 1.19. The business has a 50-day simple moving average of $14.75 and a 200 day simple moving average of $14.71. NeoGenomics has a 52 week low of $12.77 and a 52 week high of $21.22. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NEO. Blue Trust Inc. grew its position in NeoGenomics by 107.2% in the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 1,206 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of NeoGenomics during the second quarter worth about $57,000. Banque Cantonale Vaudoise grew its holdings in shares of NeoGenomics by 10.2% during the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock worth $244,000 after purchasing an additional 1,633 shares during the last quarter. Gabelli Funds LLC bought a new stake in shares of NeoGenomics during the first quarter worth about $283,000. Finally, SG Americas Securities LLC bought a new stake in shares of NeoGenomics during the third quarter worth about $312,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.